Navigation Links
Navigating the IP Minefield of Human Embryonic Stem Cell Development

FARMINGTON, Conn., May 8, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports

Opportunities in Human Embryonic Stem Cell (hESC) Products
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, the stage reached 4 to 5 days after fertilization. They are the most pluripotent of all stem cell types, able to develop into any of over 200 different cell types in the human body, rending them tremendously useful for their therapeutic potential. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for guidance for companies seeking to develop new products.

BioInformant's new Opportunities in Human Embryonic Stem Cell (hESC) Products market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market. Over the past 15 years, WARF has been the major "gatekeeper" in determining which research product companies are able to conduct research, create commercial products, and develop novel therapies using hESCs. To date, WARF has entered into licensing agreements with only 27 commercial partners for its intellectual portfolio related to isolating and differentiating hESCs.

While Invitrogen, Becton Dickinson and Chemicon have disclosed licensing agreements with WARF, many research products companies have be forced to explore less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species. This report will give readers a fuller, more complete understanding of the complex IP situation in the hESC market, before they make any costly development decisions.

An Executive Summary for this report and a free sample of the full document are available at

Capitalizing on Opportunities in Cord Blood Industry Growth
For even greater depth, companies involved in regenerative medicine research and development can turn to BioInformant's Cord Blood Industry Opportunities report to help guide future research and product design to ensure strong future sales and growth.

BioInformant's new market report "Capitalizing on Cord Blood Industry Growth" is particularly useful because it provides a direct link into the minds of a large, global population of parents, offering findings that have not been made available previously. This report also offers the most complete overview available anywhere of active global cord blood banks, tracking all 521 specific Cord Blood Banks operating in the world today.

An Executive Summary of this analysis and a free sample of the full report are available at

About Global Information Inc. Global Information (GII) ( is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796,

News distributed by PR Newswire iReach:

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Navigating in the ocean of molecules
2. Swiss Institute of Bioinformatics celebrates 10th birthday by presenting major gifts to human health
3. Scientists identify novel inhibitor of human microRNA
4. During exercise, the human brain shifts into high gear on alternative energy
5. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
6. Research shows Brazilian acai berry antioxidants absorbed by human body
7. Study: Bird diversity lessens human exposure to West Nile Virus
8. Human Microbiome Project awards funds for technology development, data analysis and ethical research
9. launches new animated 3-D views of human body in action
10. Gene with probable role in human susceptibility to pulmonary tuberculosis identified
11. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
Post Your Comments:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: